Tourette syndrome drug pipeline
- ICD-11 8A05.00
- MeSH D005879
2 compounds from 2 companies are in active clinical development for tourette syndrome, including 1 at Phase 3 or beyond.
- Filed (NDA) 1
- Phase 2 1
Mechanisms: Small molecule (1) · Neuroactive Steroid (1)
Pipeline data compiled July 2026 · every fact sourced.
Upcoming readouts & recent results
Teva submitted the U.S. NDA for ecopipam in pediatric Tourette syndrome (guided for 2H 2026; submitted 2026-06-18). ↗
D1AMOND Phase 3 met primary and secondary endpoints: ecopipam delayed time to relapse vs placebo in pediatric (HR=0.5, p=0.0084) and combined (HR=0.5, p=0.0050) Tourette populations; published in JAMA Neurology. ↗
Sepranolone Phase 2a in Tourette syndrome: 28% YGTSS tic reduction vs 12.6% control (p=0.051); all secondary endpoints (PUTS, GTS-QOL, impairment) favored sepranolone; favorable safety. ↗
Compounds in development (2)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| EcopipamOrphanFast Track | Teva Pharmaceutical Industries Ltd. | Filed (NDA) | Active | D1 receptor Antagonist |
| Sepranolone | Relmada Therapeutics, Inc. | Phase 2 | Completed | GABA-A receptor Antagonist |
Trials recruiting now (4)
4 drug-interventional tourette syndrome trials recruiting now, of 78 registered interventional trials. Browse all on ClinicalTrials.gov →
SCI-110
Sertraline
Washed Microbiota Transplantation
Tourette Syndrome (TS) children were administered Pei Tu Ning Feng Tang treatment.
Frequently asked
- How many drugs are in development for tourette syndrome?
- 2 compounds from 2 companies are in active clinical development for tourette syndrome, including 1 at Phase 3 or beyond.
- Which tourette syndrome drugs are in Phase 3?
- Phase 3 (or later) programs for tourette syndrome include Ecopipam.
- How many clinical trials are recruiting for tourette syndrome?
- 4 drug-interventional tourette syndrome trials are currently recruiting participants, out of 78 registered interventional trials.